Clinical study on the relationship between serum interleukin-35 level and prognosis of patients with clear cell renal cell carcinoma

Abstract

Objective To investigate the expression of IL-35 and determine its clinical significance in human clear cell renal cell carcinoma(ccRCC). Methods The levels of serum IL-35 in 132 patients with ccRCC and 100 healthy controls were detected by enzyme-linked immunosorbent assay (ELISA). Statistical analysis of the relationship between IL-35 levels and clinicopathological parameters and prognosis of patients with ccRCC. Results The serum IL-35 level in ccRCC patients (25.86 ± 11.78)pg / mL was significantly higher than that in healthy controls (10.05 ± 9.47) pg / mL, (P<0.001. Serum IL-35 levels were associated with pathological stage (P<0.001), fuhrman grade (P<0.001), tumor size (P=0.012), T stage (P=0.007), N stage (P=0.002) metastases (P<0.001) and recurrence (P=0.001). Kaplan-Meier survival analysis showed a significant correlation between high serum IL-35 levels and overall survival (log-rank, P<0.001). Multivariate analysis showed that serum IL-35 levels (HR=2.919, 95%CI=1.871-4.830, P=0.001) and pathological stage (HR=2.541, 95%CI=1.227-3.987, P=0.002) were independent prognostic factors for overall survival in ccRCC patients. Conclusions High levels of IL-35 are associated with poor prognosis in ccRCC patients. IL-35 may become a promising prognostic biomarker for ccRCC. Key words: Kidney Neoplasms; Interleukins; Prognosis